Evidence map›Paper›PMID 40425926›Full record

ArticleBreast cancer research and treatment2025

Subtype-specific dysregulation of biogenic amine-related genes and miRNAs in breast cancer: identification of DRD2, HRH2, and HRH4 as potential therapeutic targets in TNBC and HER2+ subtypes.

Agata Sirek, Tomasz Sirek, Robert Nowakowski, Przemysław Borawski, Piotr Ossowski, Elżbieta Mitka-Krysiak, Nikola Zmarzły, Kacper Boroń, Michał Chalcarz, Bernadeta Kuraszewska and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Agata SirekDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland. agatasirek06@gmail.com.
Tomasz SirekDepartment of Plastic and Reconstructive Surgery, Hospital for Minimally Invasive and Reconstructive Surgery in Bielsko-Biała, 43-316, Bielsko-Biala, Poland.
Robert NowakowskiDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Przemysław BorawskiIndependent Researcher, 87-800, Włocławek, Poland.
Piotr OssowskiDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Elżbieta Mitka-KrysiakDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Nikola ZmarzłyDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Kacper BorońDepartment of Plastic Surgery, Faculty of Medicine, Academia of Silesia, 40-555, Katowice, Poland.
Michał ChalcarzDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Bernadeta KuraszewskaDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Mariola SzulikDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Dariusz BorońDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.
Beniamin Oskar GrabarekDepartment of Medical and Health Sciences, Collegium Medicum, WSB University, 41-300, Dabrowa Górnicza, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBiogenic amines (BAs) are known to influence tumorigenesis, yet their precise role in breast cancer remains unclear. This study aimed to investigate the expression patterns of BA-related genes, proteins, and their regulatory miRNAs across different breast cancer subtypes to identify potential biomarkers and therapeutic targets.

methodsA cohort of 501 breast cancer patients was classified into luminal A (n = 130), luminal B HER2- (n = 100), luminal B HER2+ (n = 96), non-luminal HER2+ (n = 36), and triple-negative breast cancer (TNBC; n = 43). Gene expression was assessed via microarray analysis and validated using RT-qPCR. Protein levels were quantified using ELISA, while miRNA profiling was conducted to identify post-transcriptional regulatory interactions. Statistical significance was determined using ANOVA and Tukey's post-hoc test (p < 0.05).

resultsHistamine-related genes (HRH1-HRH4) were upregulated across all subtypes, with HRH2 and HRH4 most elevated in TNBC (FC = 7.18, p < 0.01). DRD2 showed widespread upregulation (FC = 15.98, p < 0.001), whereas DRD5 was markedly downregulated, especially in non-luminal HER2+ tumors (FC =  - 13.01, p < 0.01). miRNA analysis revealed downregulation of hsa-miR-30b-3p and hsa-miR-372-5p in TNBC and HER2+ subtypes, correlating with HRH2 and HRH4 overexpression (p < 0.05). EGR1 and ICAM1 exhibited strong subtype-specific expression, with ICAM1 significantly upregulated in TNBC (FC = 25.76, p < 0.001).

conclusionSubtype-specific dysregulation of BA-related genes and miRNAs suggests their involvement in tumor progression, immune modulation, and metabolic regulation. The findings highlight potential therapeutic targets, particularly in TNBC and HER2+ subtypes.

Indexed as

Biogenic AminesErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticMicroRNAsReceptors, Dopamine D2Receptors, G-Protein-CoupledTriple Negative Breast NeoplasmsAdultAgedBiomarkers, TumorFemaleGene Expression ProfilingHumansMiddle AgedBiogenic AminesBiomarkers, TumorDRD2 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMicroRNAsReceptors, Dopamine D2Receptors, G-Protein-CoupledBiogenic aminesBreast cancerDopaminergic systemHistaminergic systemMicro RNA

Identifiers

PMID40425926
PMCPMC12133955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.